The “American (cancer) patients first” plan to reduce drug prices-A critical assessment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The “American (cancer) patients first” plan to reduce drug prices-A critical assessment

Published:2018-10-09 Issue:12 Volume:93 Page:1444-1450
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Kantarjian Hagop¹^ORCID,Light Donald W.²,Ho Vivian³

Affiliation:

1. Leukemia Department; MD Anderson Cancer Center; Houston Texas

2. Rowan University School of Osteopathic Medicine; Cherry Hill New Jersey

3. James A. Baker III Institute Chair in Health Economics and Director, Center for Health and Biosciences; Rice University; Houston Texas

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25284/fullpdf

Reference103 articles.

1. Managing oncology costs;Reeder;Am J Manag Care,2006

2. American Society of Clinical Oncology guidance statement: the cost of cancer care;Meropol;J Clin Oncol,2009

3. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts;Experts in Chronic Myeloid Leukemia;Blood,2013

4. In support of a patient-driven initiative and petition to lower the high Price of cancer drugs;Tefferi;Mayo Clin Proc,2015

5. Why are cancer drugs so expensive in the United States, and what are the solutions?;Kantarjian;Mayo Clin Proc,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors;Journal of the National Comprehensive Cancer Network;2024-02

2. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results;Clinical Lymphoma Myeloma and Leukemia;2023-10

3. Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019;Cancer;2023-09-28

4. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA;The Lancet Haematology;2022-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3